<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082548</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00049709</org_study_id>
    <nct_id>NCT02082548</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation</brief_title>
  <acronym>IMPACT-AF</acronym>
  <official_title>An International Multicenter Clustered Randomized Controlled Trial to imProve Treatment With AntiCoagulanTs in Patients With Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Romania: Ethics Committee</authority>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>India: Indian Council of Medical Research</authority>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether a comprehensive evaluation and customized multilevel educational
      interventions will increase the rate of use of oral anticoagulants and the adherence and
      persistence of use in patients with atrial fibrillation. Our hypothesis is that there will
      be differences in the use of oral anticoagulants and the persistence in patients between the
      control and interventional group. There will be a greater change in the use of oral
      anticoagulants over one year in the cohort in the intervention sites than the control sites.
      This will be due to two factors: greater initiation of oral anticoagulants among patients
      not treated at baseline and greater persistence of treatment for those on treatment at
      baseline
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in proportion of patients taking oral anticoagulants</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in proportion of patients taking oral anticoagulants from baseline to one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of patients able to continue anticoagulation</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in proportion of patients able to continue anticoagulation for one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of patients who are not on anticoagulation at baseline and are on anticoagulation</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in proportion of patients who are not on anticoagulation at baseline and are on anticoagulation at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, total</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke, hemorrhagic and non-hemorrhagic</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and non-major clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Systemic Embolism</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Transient Ischemic Attack</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalizations for cardiovascular causes</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Time in therapeutic range for patients on vitamin K antagonists (VKA)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>educational intervention arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational Intervention</intervention_name>
    <description>This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients over the age of 18 with paroxysmal, persistent or permanent atrial
             fibrillation who have a 12-lead ECG showing atrial fibrillation and/or more than one
             rhythm strip showing atrial fibrillation at least 2 weeks apart, not due to a
             reversible cause (like post-CABG))

          -  2. At least one of the traditional CHADS2 risk factors or at least two CHA2DS2 VASc
             risk factors

        Exclusion Criteria:

          -  Mechanical prosthetic valve

          -  Clinically unstable at the time of enrollment (ie, with ongoing shock)

          -  Terminal illness and/or comfort care

          -  Unable to provide consent (e.g. severe cognitive impairment)

          -  Patients unable to have one year of follow-up for any reason

          -  Clear and absolute contraindication to oral anticoagulation (for example, active
             bleeding or recent life-threatening bleeding such as ICH)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher B Granger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INECO Neurosciencias Orono</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meena Rao, MD, MPH</last_name>
      <phone>919-668-8936</phone>
    </contact>
    <investigator>
      <last_name>Maria Cecilia Bahit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meena Rao, MD MPH</last_name>
      <phone>9196688936</phone>
    </contact>
    <investigator>
      <last_name>Renato D Lopes, MD, MHS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meena Rao, MD, MPH</last_name>
      <phone>919-668-8936</phone>
    </contact>
    <investigator>
      <last_name>Huo Yong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Johns Medical College</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meena Rao, MD, MPH</last_name>
      <phone>919-668-8936</phone>
    </contact>
    <investigator>
      <last_name>Denis Xavier, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Medicina and Pharmacy Carol Davila</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meena Rao, MD</last_name>
      <phone>9196688936</phone>
    </contact>
    <investigator>
      <last_name>Dragos Vinereanu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>China</country>
    <country>India</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>education</keyword>
  <keyword>educational intervention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
